In this article
“IgG antibodies are not diagnostic”
The guidance of Hungarian professional bodies refers to IgG, or more precisely IgG₄, in the context of food allergy (IgE-mediated) and tolerance, not to IgG-mediated food sensitivity tests.
Food-specific total IgG testing (subclasses 1–4) detects immune complexes that are characteristic of type III hypersensitivity. This is an entirely different mechanism from food allergy triggered by IgE antibodies or from intolerances caused by enzyme deficiency (for example lactose intolerance). Total IgG tests were not designed to diagnose non-IgE-mediated food allergy, but to identify delayed, immune complex-mediated food sensitivities.
“Not scientifically proven and potentially harmful”
Most position statements (for example those of the Hungarian Dietetic Association, MDOSZ, and the Hungarian Society of Allergology and Clinical Immunology, MAKIT) simply adopt the 2008 EAACI consensus on IgG₄, completely disregarding all scientific evidence on total IgG testing. They do not address type III reactions or total IgG tests at all.
We agree that unsupervised elimination diets carry risks; this is precisely why we advise our patients to have their results interpreted by an appropriately trained professional, and we likewise do not recommend IgG₄-based tests.
“Only a few studies show meaningful benefits”
- The survey by Hardman & Hart (2007) and the randomised, placebo-controlled study by Atkinson et al. (2004) relied on subjective endpoints.
- Newer, more rigorous evidence of objective benefits:
- Singh et al. (2025): a randomised, placebo-controlled study in IBS patients showed that an elimination diet based on IgG test results led to significant symptom relief compared with the placebo group.
- Lieners & Wasiluk (2020): a prospective study showed that an IgG-guided elimination–rotation diet performed better than the low-FODMAP diet and the standard IBS diet.
- Garmendia et al. (2025): They described in detail how food-specific IgG and IgG₄ contribute to both intolerance and tolerance, emphasising the clinical relevance of total IgG testing and the importance of the roles of the different IgG subclasses.
“Position statements”
The 2022 position statement of MDOSZ states clearly:
“These tests have no clinical use either in the diagnosis of food allergy or in the diagnosis of non-immune-mediated food sensitivities.”
As mentioned above, we do not recommend food-specific IgG testing either for food allergy (IgE-mediated) or for non-immune-mediated food intolerance (for example lactose intolerance). In addition, every study cited by MDOSZ examines IgE-mediated allergy and the IgG₄ response to IgE allergens – entirely different pathways from the type III total IgG immune complexes that our tests measure. In other words, the MDOSZ warning applies to IgG tests interpreted in the context of IgE allergy (e.g. egg, milk, peanut) or non-immune-mediated food intolerance, not to quantitative total IgG tests that investigate delayed food sensitivity.
Our clinically validated total IgG microarray tests focus on immune complex-mediated reactivity, not on IgE-mediated allergy with immediate symptoms. Because of this difference, our food intolerance test does not fall within the scope of the IgG₄-specific guidance in the position statements above. Rather, it highlights the test’s role alongside established diagnostic tools (e.g. breath tests, coeliac serology), naturally under the supervision of an appropriate professional.
“Children and restrictive diets”
We fully agree that elimination diets for children must be carried out with the involvement of a paediatric dietitian or paediatrician. Our guidance states that testing is not recommended for children under 2 years of age.
Our information materials contain clear warnings that specialist medical or dietetic supervision is necessary for every child.
“On marketing”
Our marketing materials and our website clearly distinguish food sensitivity (type III, total IgG) from food allergy (type I, IgE), and we avoid implying that our tests diagnose IgE-mediated allergy.
“FSA research findings”
The FSA (Food Standards Agency) statement that IgG responses are part of normal immunological tolerance refers to the role of IgG₄ in tolerance and does not take into account the pathological potential of IgG1–3 immune complexes in type III reactions. Distinguishing between the two is crucial, yet these tests are routinely disregarded and conflated.
The FSA’s original work on the relationship between IgG and food tolerance was produced in 2006 and was last cited in a guideline in 2016 – that is, nearly two decades ago. The 2024 project funded by the FSA (“Patterns and prevalence of adult food allergy”), however, emphasised the complex spectrum of immune-mediated food reactions and drew attention to the need for a deeper investigation of non-IgE antibody profiles.
Although this study did not specifically evaluate IgG testing, its results highlight that serological markers beyond IgE also correlate with symptom patterns and can help stratify patients for targeted dietary interventions.
Overall, this new FSA research supports the value of professional, quantitative total IgG testing when it is interpreted by clinicians and used to guide elimination diets and to improve symptoms.
Conclusions:
- A different purpose: Total food-specific IgG testing reveals type III hypersensitivity, not IgE allergy or simple enzyme-deficiency intolerance.
- Outdated guidance: Every major position statement can be traced back to the same 2008/2010 consensus, which concerns IgG₄ only, with no updates regarding total IgG testing.
- Growing evidence: Newer, high-quality studies (Singh et al. 2025; Lieners & Wasiluk 2020; Garmendia et al. 2025) support clinical usefulness in IBS and beyond.
- Responsible use: When interpreted by healthcare professionals within a multidisciplinary framework, IgG-guided elimination diets can safely and effectively relieve symptoms that have remained beyond the reach of conventional approaches.